Some deaf children are hearing again because of a new gene therapy
SMRTR summary
A toddler born deaf began responding to sound just six weeks after receiving a single gene therapy injection. The FDA approved Otarmeni, made by Regeneron, on April 23, after 80% of trial patients gained measurable hearing. Gene therapy nearly died after a 1999 patient death but recovered through safer delivery methods. The main challenge now is cost — similar treatments run up to $3.5 million.
SMRTR provides this summary for quick context. The original article belongs to Recode.
Read the original article